gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request Ein Cyf / Our Ref: 23-C-010

Please note that we have provided this information for the period May to October 2022 (the last complete period available).

You asked:

- 1. How many patients were treated in the past 6 months (for any disease) with:
 - Ruxolitinib 9 patients
 - Fedratinib <5 patients
- 2. Does your Health Board treat myeloproliferative neoplasms? If not, which other Health Board do you refer these patients to?

 Yes
- 3. Please provide the total number of patients treated in the last 6 months for:
 - Polycythaemia Vera (ICD10 code D45) 9 patients (16 admissions)
 - Myelofibrosis (ICD10 code D47.4) 7 patients (38 admissions)
 - Myelofibrosis (ICD10 code D47.4) patients aged 65 and older 5 patients (9 admissions)
- 4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:
 - Polycythaemia Vera (ICD10 code D45)
 - Myelofibrosis (ICD10 code D47.4)

I can confirm that our Pharmacy system does not record this information by type of myeloproliferative disorder. A total of 9 patients treated across both disorders.

5. How many myelofibrosis (ICD10 code D47.4) patients has your Health Board diagnosed in the past 3 years?

I can confirm that this information is not held centrally. To obtain this information would involve a manual trawl and search of records which we have estimated



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

- Of the patients diagnosed with myelofibrosis in the past 3 years, how many were treated in the past 6 months with Hydroxycarbamide?
 Please see above
- Of the patients diagnosed with myelofibrosis in the past 3 years, how many were treated in the past 6 months with Interferon therapy?
 Please see above
- Of the patients diagnosed with myelofibrosis in the past 3 years, how many have received no active treatment in the past 6 months?
 Please see above

*Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.